Integrative Treatment and Management for Hyperparathyroidism

Learn about holistic approaches to hyperparathyroidism integrative treatment that promote overall well-being and balance

Educational Abstract: Integrative Insights on Primary Hyperparathyroidism, Quality of Life, and Multidisciplinary Care

Welcome to this comprehensive educational guide on hyperparathyroidism, a condition often characterized by the overproduction of parathyroid hormone (PTH), which plays a crucial role in regulating calcium levels in our blood and bones. In this post, we will embark on a detailed, evidence-based journey to understand the intricacies of hyperparathyroidism, starting with its primary symptom: hypercalcemia, or elevated calcium levels. I will explain how calcium, vitamin D, and PTH regulate human physiology; how laboratory and imaging modalities clarify diagnosis; and how surgical and medical strategies are selected, sequenced, and personalized. We will delve into the different types of hyperparathyroidism—primary, secondary, and tertiary—and discuss the clinical criteria that guide treatment decisions, particularly the indications for surgery, which remains the only definitive cure.
This post will also cover medical management options, including medications like Cinacalcet (Sensipar) and bisphosphonates, and highlight the importance of an integrated, multidisciplinary approach. I will explain how our unique practice model at the Injury Medical Clinic PA in El Paso, Texas, brings together the expertise of Dr. Maria Guadalupe Cardenas, MD, a highly experienced board-certified internist serving as our Medical Director, with my own background in chiropractic, functional medicine, and as a Family Nurse Practitioner. This collaborative framework allows us to provide holistic, evidence-based care that addresses the musculoskeletal, metabolic, and systemic aspects of hyperparathyroidism. Join me as we explore the latest findings from leading researchers, translate them into actionable clinical protocols, and share real-world observations from my practice to turn “calcium chaos” into clarity.

Calcium Chaos Made Understandable: A First-Person Educational Journey

I have spent decades observing how subtle shifts in calcium physiology reverberate through the nervous system, musculoskeletal integrity, kidney function, and cognitive well-being. What may appear as a simple “high calcium” on a routine lab can conceal years of bone remodeling imbalance, silent nephrolithiasis, accelerating vascular calcification, and progressive neurocognitive changes. When I first encountered patients with unexplained fatigue, recurrent musculoskeletal pain, and vague gastrointestinal symptoms, I noticed a pattern—”normal” ranges did not explain their day-to-day experience. That realization led me to dig into the physiology behind calcium chaos and build a multidisciplinary pathway with medical, functional, and chiropractic expertise, guided by rigorous research.
In this educational post, I will:

• Define primary hyperparathyroidism and differentiate it from secondary and tertiary forms.
• Explain the physiological roles of calcium, vitamin D (D3 and D2), PTH, and phosphorus.
• Discuss laboratory tests including serum calcium, albumin-adjusted calcium, ionized calcium, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, urinary calcium excretion, and phosphorus.
• Review imaging modalities: neck ultrasound, sestamibi scintigraphy, 4D-CT, and MRI.
• Outline medical management strategies, including hydration, antiresorptives, and cinacalcet.
• Detail indications and protocols for parathyroidectomy, with modern minimally invasive methods.
• Illustrate how integrative chiropractic care fits into comprehensive management—addressing posture, pain, fracture prevention, and rehabilitation.
• Integrate functional medicine frameworks for root-cause investigation, including nutrition, microbiome, and stress physiology.
• Present personal injury considerations and case-style narratives connecting physiological insights to clinical decisions.
• Cite leading researchers, synthesize current literature, and provide APA-7 in-text citations with linked references.

My goal is to make this journey readable and relatable: to take you step-by-step across the terrain of hyperparathyroidism and its practical, integrative care.

Meet Our Collaborative Team: Internal Medicine and Chiropractic in an Integrative Clinic

At the Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, we have cultivated a unique, multidisciplinary environment dedicated to providing comprehensive and patient-centered care. A cornerstone of our practice is the collaborative relationship between me, Dr. Alex Jimenez, and our esteemed Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with an impressive career spanning over 40 years (NPI #1164426749, Texas MD License #J2933). Her vast experience and deep understanding of internal medicine provide the essential medical oversight that underpins our integrative model.
This partnership allows us to blend the best of multiple disciplines. My expertise as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) specializing as a Family Nurse Practitioner (FNP-BC), combined with advanced certifications in functional and integrative medicine, focuses on the body’s structure, function, and underlying metabolic pathways. Dr. Cardenas’s role as the supervising physician is crucial. She provides the medical direction necessary to diagnose and manage complex internal conditions like PHPT, prescribe medications, order labs and imaging, and ensure that all aspects of our patients’ care meet the highest medical standards. This setup is common in leading-edge integrative and injury care clinics, where the synergistic expertise of a Medical Doctor (MD) and a Doctor of Chiropractic (DC) creates a powerful therapeutic alliance.
Together, our team integrates:

• Medical Diagnosis and Management (Dr. Cardenas): Providing primary medical assessment, oversight of complex endocrine conditions, and prescription management.
• Chiropractic Care (Dr. Jimenez): Focusing on spinal and joint alignment, nervous system function, and biomechanical health to reduce pain and improve mobility.
• Functional Medicine (Dr. Jimenez): Investigating the root causes of chronic illness by analyzing genetics, lifestyle, and environmental factors to create personalized health strategies.
• Rehabilitation and Personal Injury Care: Developing customized programs to help patients recover from injuries, restore function, and prevent future issues.
• Nutritional and Lifestyle Counseling: Guiding patients toward optimal health through diet, exercise, and stress management techniques.

This integrated model ensures that when a patient presents with a condition like hyperparathyroidism, we can address it from multiple angles. While Dr. Cardenas oversees the medical diagnosis and management of the endocrine disorder, I can implement supportive chiropractic and functional medicine protocols to manage associated symptoms like bone pain, muscle weakness, and fatigue, and to optimize overall metabolic health. This holistic approach empowers our patients on their journey to wellness.

The Historical Perspective: Early Recognition and Surgical Milestones

The first diagnosis of hyperparathyroidism was documented in 1926 by Dr. Eugene Dubois, whose patient, Captain Charles Martel, suffered progressive skeletal disease and repeated surgeries until a parathyroid adenoma was discovered. His case, dramatic and tragic, foreshadowed the intimate link between parathyroid pathology and bone. Historically, before the widespread use of routine biochemical screening that began around 1970, this condition was known by the memorable triad of “bones, stones, and abdominal groans.” Patients were often symptomatic, presenting with bone pain, kidney stones, and gastrointestinal issues. Today, surgical finesse and biochemical understanding enable earlier identification and curative procedures, reducing the severe bone and renal complications that tormented early patients.

Identifying High Calcium: The First Step in the Diagnostic Journey

When we begin to investigate conditions like hyperparathyroidism, our journey often starts with a simple, yet profoundly important, lab finding: hypercalcemia, or an elevated level of calcium in the blood. While hyperparathyroidism is a primary suspect, it is by no means the only cause. As a clinician, my first responsibility is to consider a broad differential diagnosis to ensure we are not overlooking other serious conditions. High calcium levels, particularly those exceeding 12 mg/dL, demand a thorough and systematic evaluation.
Here are some of the critical conditions we must consider when a patient presents with hypercalcemia:

• Hypercalcemia of Malignancy: This is one of the most serious considerations. Certain cancers can produce a substance called parathyroid hormone-related peptide (PTHrP), which mimics the action of PTH and causes calcium to be released from the bones. Other malignancies, such as multiple myeloma or cancers that have metastasized to the bone, can directly destroy bone tissue, releasing calcium into the bloodstream.
• Vitamin D or Vitamin A Toxicity: In our modern world of supplements, it’s not uncommon for individuals to overdo it. Excessive intake of vitamin D can increase calcium absorption from the gut, resulting in hypercalcemia. Similarly, though less common, vitamin A toxicity can also affect bone metabolism and elevate calcium levels.
• Milk-Alkali Syndrome: This condition arises from the ingestion of large amounts of calcium and absorbable alkali, typically from over-the-counter antacids. I recall a recent case in our clinic that perfectly illustrates this point. A patient presented with significantly high calcium levels. During our detailed consultation, a crucial part of the functional medicine approach, we explore every aspect of a patient’s lifestyle, including supplements. When I asked her specifically about any over-the-counter products she was taking, she mentioned using Tums for indigestion. The follow-up question is always about quantity. When I asked how many she was taking, she revealed she was consuming about thirty Tums per day. This crucial piece of information immediately pointed us toward the cause of her hypercalcemia. It underscores the absolute necessity of asking detailed, quantified questions during the patient history.
• Other Potential Causes: The list of possibilities extends further. We also consider:
  • Prolonged Immobilization: Patients who are bedridden for long periods can experience increased bone resorption, leading to a release of calcium.
  • Hyperthyroidism: An overactive thyroid gland can accelerate bone turnover and cause mild hypercalcemia.
  • Granulomatous Diseases: Conditions like sarcoidosis or tuberculosis (TB) can lead to the formation of granulomas, which can activate vitamin D and subsequently raise calcium levels.
  • Medications: Certain drugs like thiazide diuretics and lithium can disrupt calcium homeostasis.
  • Adrenal Insufficiency: A deficiency in adrenal hormones can sometimes be associated with hypercalcemia.
  • Total Parenteral Nutrition (TPN): Patients receiving all their nutrition intravenously can sometimes develop imbalances in their calcium levels.

Understanding this broad landscape is the first step in a precise and effective diagnostic process.

Clinical Pearls for Navigating an Elevated Calcium Result

When routine lab work reveals an elevated serum calcium level, it’s essential not to jump to conclusions. A calm, methodical approach is key. Here are some “clinical pearls”—practical steps and considerations—that I follow in my practice to navigate this finding effectively.

The First Step: Recheck and Confirm

The very first action I take when I see an isolated elevated serum calcium result is simple: recheck it. Lab errors can happen, and transient fluctuations can occur. I will have the patient come back for a repeat blood draw, ideally under controlled conditions (e.g., fasting). If the repeat test comes back normal and there are no other red flags in the patient’s history or exam, we can often monitor the situation. I might say, “Let’s move on for now, but we’ll keep an eye on this in future lab panels.” If the elevation reappears on a subsequent test down the line, then a more thorough investigation is warranted. However, if a single repeat test normalizes, we can often avoid an unnecessary and potentially costly workup.

The Second Step: Deepen the Investigation

If the repeat calcium level is also elevated, our investigation deepens. This is the point where we need more data to understand the underlying physiology. The next logical and crucial test to add is a parathyroid hormone (PTH) level. This single test is the most important differentiator. The relationship between calcium and PTH tells us a story:

• High Calcium + High PTH: This combination strongly suggests primary hyperparathyroidism, where the parathyroid glands are autonomously overproducing the hormone.
• High Calcium + Low PTH: This pattern indicates that the parathyroid glands are functioning correctly—they are trying to shut down production in response to the high calcium. This points us toward other causes, such as malignancy or vitamin D toxicity.

Considering Ionized Calcium

You might also consider ordering an ionized calcium level. Total serum calcium, which is what is measured in a standard metabolic panel, is about 50% bound to proteins, primarily albumin. The other 50% is the “free” or “ionized” calcium, which is the biologically active form. Ionized calcium directly interacts with the calcium-sensing receptor (CaSR) on parathyroid chief cells, guiding PTH secretion. Changes in albumin levels can affect the total calcium measurement without changing the active ionized calcium. For instance, in a dehydrated patient with high albumin, the total calcium might appear falsely elevated.
We often use a formula to calculate a “corrected calcium” based on the albumin level. However, ordering a direct ionized calcium test can sometimes provide a more accurate picture, especially when albumin is abnormal, acid-base status is unstable, or when clinical symptoms diverge from total calcium readings. It’s important to remember, though, that in a relatively healthy individual with a normal acid-base status, the corrected calcium is often sufficient.

The Physiology of Calcium: Roles, Regulation, and Resonance

Calcium is more than a bone mineral; it is a signaling ion orchestrating countless processes.

• Cardiac conduction: Calcium influx drives the plateau phase of action potentials; abnormalities can precipitate arrhythmias.
• Neuromuscular function: Calcium binds troponin C, enabling muscle contraction. Hypercalcemia can alter excitability, causing weakness or fatigue.
• Neurotransmission: Presynaptic calcium influx triggers synaptic vesicle release; dysregulation affects cognition and mood.
• Coagulation: Calcium (Factor IV) is essential for activating various clotting cascades.
• Bone remodeling: Calcium combines with phosphate in hydroxyapatite; osteoclast and osteoblast balance hinges on PTH and vitamin D.

Serum calcium exists in three fractions:

• Protein-bound (mostly to albumin): Not bioactive; shifts with albumin changes.
• Complexed (bound to anions such as citrate, phosphate).
• Ionized (free): The bioactive fraction; tightly regulated, it reflects the true physiologic impact.

Symptoms of Hypercalcemia: Thresholds and Clinical Nuance

• Mild elevations (around 10–11 mg/dL): Often asymptomatic or subtle—fatigue, constipation, mild mood changes.
• Moderate elevations (>11 mg/dL): Nausea, abdominal pain, anorexia, cognitive changes, dehydration, decreased exercise tolerance.
• Severe elevations (≥12–14 mg/dL): Neurocognitive impairment, acute kidney injury, arrhythmias, altered mental status; can become life-threatening.

In emergency settings, patients may be obtunded with acute renal compromise. Rapid stabilization—IV hydration, loop diuretics (after volume repletion), calcitonin, and consideration of bisphosphonates—is essential. Our integrated team prioritizes assessment of the underlying cause: PHPT, malignancy, granulomatous disease, thyrotoxicosis, drug-induced hypercalcemia, immobilization, vitamin A toxicity, and milk-alkali syndrome.

Understanding the Types of Hyperparathyroidism: Primary, Secondary, and Tertiary

Hyperparathyroidism is not a single entity. It is categorized into three distinct types—primary, secondary, and tertiary—each with a different underlying cause and physiological mechanism. Understanding these distinctions is fundamental to accurate diagnosis and treatment.

Primary Hyperparathyroidism

Primary hyperparathyroidism (PHPT) is the focus of our discussion. In this condition, the problem originates within the parathyroid glands themselves. One or more of the four parathyroid glands develops a benign tumor, called an adenoma, or, less commonly, becomes enlarged, a condition known as hyperplasia. This abnormal gland tissue becomes autonomous and produces an excessive amount of parathyroid hormone (PTH), irrespective of the body’s actual calcium levels.
The normal feedback loop is broken. In a healthy individual, high blood calcium would signal the parathyroid glands to stop producing PTH. In PHPT, the adenoma continues to churn out PTH, leading to a classic biochemical signature:

• High Serum Calcium
• High or Inappropriately Normal PTH

Secondary Hyperparathyroidism

In secondary hyperparathyroidism, the parathyroid glands are not the source of the problem. They are actually functioning correctly, but they are responding to another underlying disease state that is causing low calcium levels (hypocalcemia). The glands become enlarged and overproduce PTH as a compensatory mechanism to try and raise the blood calcium back to normal.
The most common causes of secondary hyperparathyroidism are:

• Chronic Kidney Disease (CKD): This is the most prevalent cause. As kidney function declines, the kidneys are unable to excrete phosphate effectively and lose the ability to activate vitamin D. The combination of low calcium and high phosphate creates a powerful stimulus for the parathyroid glands to produce massive amounts of PTH.
• Vitamin D Deficiency: A severe and prolonged deficiency of vitamin D leads to poor calcium absorption from the diet, triggering the parathyroid glands to ramp up PTH production.

The biochemical profile of secondary hyperparathyroidism is typically: Low or Normal Serum Calcium and High PTH.

Tertiary Hyperparathyroidism

Tertiary hyperparathyroidism is a complication that arises from long-standing, severe secondary hyperparathyroidism, most often in patients with end-stage renal disease. After years of constant stimulation, the parathyroid glands become so enlarged and hyperplastic that they begin to function autonomously, similar to a primary adenoma. They continue to secrete massive amounts of PTH even if the original problem is corrected (e.g., after a kidney transplant), leading to significant hypercalcemia.
The biochemical profile of tertiary hyperparathyroidism is: High Serum Calcium and Very High PTH.

Differentiating the Causes of Elevated Calcium and PTH

When we have confirmed that a patient has both elevated calcium and elevated parathyroid hormone (PTH), we have significantly narrowed our differential diagnosis. The primary culprit we focus on is primary hyperparathyroidism. However, before finalizing this diagnosis, it’s crucial to rule out other factors that can create a similar lab profile.

The Role of Medications

• Thiazide Diuretics: Medications like hydrochlorothiazide (HCTZ) increase the reabsorption of calcium from the urine back into the blood. This can lead to elevated serum calcium levels and a slightly elevated PTH. In such cases, if clinically appropriate, I work with the patient’s primary care provider to temporarily hold the diuretic and recheck labs.
• Lithium: This medication, used for bipolar disorder, increases the “set point” for calcium, desensitizing the parathyroid glands to calcium. The result is both hypercalcemia and elevated PTH. Managing this requires close collaboration with the patient’s mental health provider.

Rare Genetic Conditions

• Familial Hypocalciuric Hypercalcemia (FHH): This is a benign autosomal dominant genetic disorder that affects the calcium-sensing receptor (CaSR). This leads to lifelong mild hypercalcemia, inappropriately normal or mildly elevated PTH, and low urinary calcium excretion (hypocalciuria). The key diagnostic test is a 24-hour urine calcium collection. A very low result (calcium-to-creatinine clearance ratio < 0.01) points to FHH, a condition that does not benefit from parathyroid surgery.
• Familial Hyperparathyroidism and Multiple Endocrine Neoplasia (MEN) Syndromes: If I encounter a patient with primary hyperparathyroidism who is under the age of 30, a red flag is immediately raised. This early onset suggests a possible genetic predisposition, such as Multiple Endocrine Neoplasia (MEN) type 1 (Parathyroid, Pituitary, Pancreatic tumors) or type 2A (Medullary thyroid cancer, Pheochromocytoma, Parathyroid hyperplasia). These patients often have multi-gland involvement and require genetic testing and lifelong screening.

A Visual Guide to Interpreting Lab Results

To simplify the process of differentiating these conditions, I find visual aids to be incredibly helpful. The following breakdown provides a clear framework for interpreting the key lab values: calcium and PTH.

Serum Calcium	Parathyroid Hormone (PTH)	Probable Diagnosis
High	High or Normal	Primary Hyperparathyroidism or Tertiary Hyperparathyroidism
Normal	High	Normocalcemic Primary Hyperparathyroidism or Secondary Hyperparathyroidism
Low	High	Secondary Hyperparathyroidism
High	Low	Hypercalcemia of Malignancy, Vitamin D Toxicity, etc.
Low	Low	Hypoparathyroidism

A Closer Look at Normocalcemic Primary Hyperparathyroidism

One of the more challenging diagnostic puzzles is Normocalcemic Primary Hyperparathyroidism (NPHPT). This is a distinct subgroup of patients who have persistently elevated PTH levels but consistently normal total and ionized calcium levels. Diagnosing NPHPT requires a careful and systematic process of exclusion. We must be certain that we are not dealing with a case of secondary hyperparathyroidism.
The key criteria for diagnosing NPHPT are:

1. Normal Calcium Levels: Confirmed over several tests.
2. Elevated Parathyroid Hormone (PTH): Confirmed on at least two separate occasions.
3. Exclusion of All Secondary Causes: This is the most critical step and involves a comprehensive workup to rule out Vitamin D Deficiency (level must be >30 ng/mL), Renal Insufficiency (GFR must be >60 mL/min), and the influence of medications or malabsorption issues.

Only after this exhaustive process can we confidently diagnose NPHPT. It is considered an early form of primary hyperparathyroidism, and studies have shown that a significant percentage of these patients will eventually progress to develop hypercalcemia over time.

The Essential Diagnostic Workup for Primary Hyperparathyroidism

Once we suspect primary hyperparathyroidism, a structured and comprehensive workup is necessary to confirm the diagnosis, assess its severity, and determine the best course of treatment.

Crucial Laboratory Tests

1. Comprehensive Metabolic Panel (CMP): Provides Serum Calcium, Albumin (to calculate corrected calcium), and Renal Function (Creatinine/eGFR).
2. Intact Parathyroid Hormone (PTH): The cornerstone test. An elevated or “inappropriately normal” PTH level in the presence of high calcium confirms the diagnosis.
3. 25-Hydroxy Vitamin D: Essential to rule out vitamin D deficiency as a cause of secondary hyperparathyroidism.
4. Serum Phosphorus: Often low or low-normal in PHPT because PTH causes the kidneys to waste phosphate.
5. 24-Hour Urine Collection for Calcium and Creatinine: Vital to assess kidney stone risk and to differentiate PHPT from Familial Hypocalciuric Hypercalcemia (FHH).

Essential Imaging Tests

These imaging studies are not used to diagnose the condition, but to stage its severity and help determine if a patient meets criteria for surgery.

1. DEXA Scan (Dual-Energy X-ray Absorptiometry): A bone mineral density scan is crucial to evaluate for osteoporosis. We must specifically request a measurement of the distal one-third radius (the forearm), a site rich in cortical bone, which is preferentially affected by high PTH levels.
2. Renal Imaging (Ultrasound, CT, or X-ray): We need to look for evidence of kidney stones (nephrolithiasis) or calcium deposits in the kidney tissue (nephrocalcinosis).
3. Pre-operative Localization Imaging (Neck Ultrasound and Sestamibi Scan): These tests are ordered only after the decision for surgery is made. Their sole purpose is to help the surgeon locate the abnormal parathyroid gland(s) before the operation. 4D-CT and MRI are other options for challenging cases.

“Cracking the Low Thyroid Code: A Comprehensive Assessment Guide”- Video

Global Differences in PHPT Presentation: The Tale of Two Cities

In a comparative study that I refer to as “The Tale of Two Cities,” investigators evaluated PHPT presentations among cohorts in the United States and Beijing, China. The findings reveal striking contrasts:
United States:

• Typical presentation: asymptomatic hypercalcemia, often in postmenopausal women.
• Average vitamin D: roughly 21 ng/mL.
• Kidney stone incidence: 15–20%.
• Skeletal involvement: primarily detected by bone densitometry.

Beijing, China:

• Average age: ~37 years, significantly younger.
• Average calcium and PTH levels are much higher.
• Average vitamin D: ~8.8 ng/mL, profoundly low.
• Radiologic osteitis fibrosa cystica is evident in ~60% of patients.
• Pathologic fractures are common (~35%).

Interpretation: Vitamin D deficiency appears as a major amplifying factor, intensifying skeletal turnover and disease severity. This highlights the importance of screening for and treating vitamin D deficiency in all PHPT patients.

Determining the Need for Surgery: Key Indications

The only definitive cure for primary hyperparathyroidism is a parathyroidectomy. However, not every patient needs surgery. International consensus guidelines have established specific criteria to identify who is most likely to benefit. A patient should be offered surgery if they meet any one of the following criteria:

Indication for Surgery	Explanation
Age < 50 years	Younger patients have a longer lifetime to suffer the consequences of untreated hypercalcemia, such as bone loss and kidney damage.
Serum Calcium Level	A serum calcium level that is more than 1.0 mg/dL above the upper limit of the laboratory’s normal range.
Bone Mineral Density	A T-score of -2.5 or lower at any of the three measured sites (lumbar spine, femoral neck, or distal 1/3 radius), which indicates osteoporosis, or a history of a fragility fracture.
Kidney Involvement	Reduced Kidney Function (eGFR of less than 60 mL/min) OR High Urine Calcium & Stone Risk (24-hour urinary calcium excretion > 400 mg/day or presence of kidney stones on imaging).

Observation vs. Surgery: Personalized Pathways and Quality of Life

For asymptomatic patients who do not meet surgical criteria, watchful waiting can be a valid approach. In fact, a significant study I often share with patients examined whether parathyroidectomy improves quality of life compared with observation. Over ten years of prospective, randomized follow-up, the study found that while surgery cured the biochemical abnormalities, it did not necessarily improve overall quality of life compared to the observation group. This empowers patients to consider non-surgical observation and teaches clinicians to avoid overpromising global life-quality improvements from surgery, while still acknowledging the clear benefits for bone and kidney health.
This is why we create a personalized plan that includes:

• Regular labs: calcium, PTH, creatinine/eGFR, vitamin D.
• Periodic DEXA scans for bone health.
• Renal ultrasounds if stone risk is present.
• Lifestyle strategies: hydration, mobility, nutrition.

The Surgical Solution and the Importance of an Experienced Surgeon

When a patient meets the criteria for surgery, the next step is a referral to a high-volume, experienced parathyroid surgeon. This cannot be overstated. These specialist surgeons have significantly higher success rates and lower complication rates.

The Surgical Procedure

The procedure, a parathyroidectomy, is highly effective, achieving a biochemical cure in approximately 98% of patients. In about 80-90% of cases, PHPT is caused by a single benign parathyroid adenoma, which can be removed through a minimally invasive approach. To confirm success, surgeons use intraoperative PTH monitoring. Since PTH has a short half-life (~3–5 minutes), a >50% drop from the baseline level after the gland is removed confirms that the source of the excess hormone has been eliminated.

The Benefits of Surgery

• Normalization of Lab Values: Serum calcium, PTH, and urinary calcium levels return to normal.
• Improvement in Bone Density: Bone density begins to improve, reducing long-term fracture risk.
• Decreased Risk of Kidney Stones: The risk of forming future kidney stones is significantly reduced.
• Potential Improvement in Neurocognitive Symptoms: Many patients report a significant improvement in fatigue, “brain fog,” and mood.

Medical Management: When Surgery Isn’t the Answer

For patients who are not surgical candidates or choose a non-surgical path, we transition to a strategy of medical management and active surveillance.

Pharmacological Intervention: Cinacalcet and Bisphosphonates

• Cinacalcet (Sensipar): For patients with significantly high calcium levels, this medication can be a game-changer. Cinacalcet is a calcimimetic, meaning it “mimics” the action of calcium. It binds to the calcium-sensing receptors on the parathyroid glands, tricking them into thinking calcium is high and causing them to decrease PTH production. This lowers both PTH and serum calcium levels. The typical starting dose is 30 mg twice a day, which can be titrated upwards based on the patient’s response.
• Antiresorptives (Bisphosphonates or Denosumab): If a patient has co-existing osteoporosis, they should be treated for it. Medications like bisphosphonates (e.g., alendronate, zoledronic acid) are effective at increasing bone density by inhibiting the osteoclasts that break down bone.

Essential Patient Education

• Hydration is Non-Negotiable: Dehydration concentrates blood calcium and can cause a dangerous spike. Patients must be vigilant about drinking plenty of fluids.
• Stay Active: Regular, weight-bearing physical activity is essential for maintaining bone health.
• Be Smart About Calcium Intake: Patients should stop taking calcium supplements. However, they should not go on a low-calcium diet, as this can backfire and further stimulate PTH production. A moderate intake of 1,000 to 1,200 mg per day from dietary sources is a reasonable goal.

The Role of Integrative Chiropractic Care in Hyperparathyroidism

While medical management focuses on controlling calcium and PTH, an integrative approach that includes chiropractic care can be profoundly beneficial for addressing the widespread musculoskeletal symptoms of the disease.
Key components of our integrative chiropractic care include:

• Biomechanical Assessment and Gentle Manual Therapy: We evaluate and treat spinal alignment, pelvic tilt, and compensatory patterns resulting from bone density changes or chronic pain. We use soft-tissue work and low-force adjustments (e.g., instrument-assisted techniques) to reduce pain and improve range of motion without stressing osteopenic bones.
• Fracture Risk Mitigation and Safety: We avoid high-velocity thrusts in patients with severe bone loss. Safety in manual therapy is paramount; we emphasize soft tissue release, joint mobilization, and motor control training over aggressive maneuvers.
• Neuromuscular Stabilization and Posture Retraining: We target deep stabilizing muscles to protect the spine and improve functional movement. We also provide ergonomic coaching and encourage movement variety to prevent immobilization-related hypercalcemia.
• Balance and Fall Prevention: Proprioceptive and vestibular training are crucial to reduce fracture risk, especially in older adults.
• Rehabilitation Integration: We design progressive resistance exercise programs tailored to bone health status. Load management through mechanotransduction is a powerful signal for improving bone strength.

My clinical observations show that coordinated manual therapy and targeted exercise significantly reduce pain and improve daily function for PHPT patients. Each intervention is selected with bone health in mind, protecting fragile structures while restoring resilience.

Functional Medicine Integration: Addressing Root Causes and Systems Biology

Our functional medicine approach complements medical and chiropractic care by addressing the whole person.

• Nutrition Strategy: We focus on adequate protein for the bone matrix, Vitamin K2 to help guide calcium to bone, magnesium sufficiency for PTH regulation, and omega-3 fatty acids to modulate inflammation.
• Gut Health: We address dysbiosis or malabsorption issues that can alter vitamin and mineral absorption.
• Sleep and Circadian Rhythm: We provide strategies to improve sleep architecture, as poor sleep impacts endocrine balance.
• Stress Physiology: We use mind-body practices like meditation and diaphragmatic breathing to reduce the negative impact of chronic stress on bone remodeling.
• Environmental and Medication Review: We identify and mitigate contributors to hypercalcemia, such as certain medications or excessive supplement intake.

Personal Injury Care: Calcium and PTH in the Context of Trauma

Injury settings introduce unique dynamics. Immobilization increases bone resorption, raising calcium and potentially dysregulating PTH. Our protocol for personal injury patients involves early mobilization plans, hydration strategies, regular lab monitoring during recovery, and nutritional support to counter catabolic stress. Dr. Cardenas’s internal medicine oversight ensures safe integration of all care, while my team provides hands-on rehabilitation to restore function without overloading weakened bone.

Case Narratives: Translating Physiology into Practice

I believe case narratives bring science to life. Here are a few that illustrate our integrative approach.

Case 1: An 85-Year-Old Female with Severe Hypercalcemia

An 85-year-old female with dementia presented to the ER with weakness and confusion, with a calcium level of 15.8 mg/dL. After ruling out malignancy, her family elected for non-surgical management. Under Dr. Cardenas’s direction, she was managed with a maximum dose of cinacalcet (90 mg twice daily), intermittent infusions of zoledronic acid, and aggressive hydration. My team focused on caregiver education, fall prevention, and gentle mobility to maintain function and safety. This case highlights how rigorous medical management can stabilize frail, high-risk patients.

Case 2: A 68-Year-Old Male with Cardiovascular Disease and PHPT

This patient was referred by his cardiologist. He met surgical criteria and underwent a successful parathyroidectomy. Post-operatively, he reported immediate improvement in energy. However, his PTH remained elevated. We identified ongoing vitamin D insufficiency as a likely contributor. Under Dr. Cardenas’s oversight, we initiated vitamin D repletion. From the chiropractic side, we supported his return to activity with a graded plan focusing on thoracic mobility and respiratory mechanics to support his cardiovascular endurance.

Case 3: A 57-Year-Old Male Pilot with PHPT and Chronic Foot Pain

This patient had elevated calcium, a non-obstructing kidney stone, and long-standing, significant bilateral foot pain. After a successful parathyroidectomy, his calcium and PTH normalized, and he reported a dramatic improvement in his chronic foot pain. This illustrates how chronic skeletal pain can be amplified by hypercalcemia. Post-operatively, I managed the mechanics of his foot and ankle, focusing on gait and strengthening, which allowed him to recover fully. Musculoskeletal pain often reflects systems biology—aligning surgical cure with biomechanical rehabilitation yields substantial functional gains.
My clinical observations and professional experience can be further explored at:

• https://chiromed.com/
• https://www.linkedin.com/in/dralexjimenez/

Frequently Asked Questions: Patient-Friendly Explanations

• Why do I feel fine if my calcium is high? Mild elevations can be “silent.” Over time, subtle symptoms emerge; early management prevents complications.
• Is surgery always necessary? Not always. Indications depend on symptoms, calcium level, bone and kidney status, and patient preference.
• Should I take vitamin D? Many benefit from careful repletion, but dosing must be personalized and monitored to avoid worsening hypercalcemia.
• What does chiropractic add? Pain relief, posture improvement, safe movement, fall prevention, and rehabilitation tailored to bone health, integrated with medical oversight.
• Will exercise help? Yes—properly dosed exercise strengthens bone and stabilizes musculoskeletal function. We design safe, progressive plans.

Closing Reflections: From Calcium Chaos to Clarity

Hyperparathyroidism spans an intricate network of bones, kidneys, nerves, and hormones. The promise of modern care—rooted in leading research and delivered through multidisciplinary integration—is that we can turn calcium chaos into clarity. With internal medicine leadership from Dr. Maria Guadalupe Cardenas and integrative chiropractic and functional medicine care at Injury Medical Clinic PA, we help patients regain control, relieve symptoms, protect their bones and kidneys, and thrive.

References

• Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, Jr., J. T. (2014). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3561–3569.
• Bilezikian, J. P. (2018). Bone disease in primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 103(8), 2892–2901.
• Brown, E. M. (2013). Role of the calcium-sensing receptor in parathyroid gland physiology. Best Practice & Research Clinical Endocrinology & Metabolism, 27(3), 333–343.
• Eastell, R., Brandi, M. L., Costa, A. G., D’Amour, P., Shoback, D. M., & Thakker, R. V. (2014). Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3570–3579.
• [Institute for Functional Medicine. (n.d.). Functional medicine approach to endocrine disorders. Retrieved from https://www.ifm.org/](https://www.ifm.org/)
• Kennel, K. A., Drake, M. T., & Hurley, D. L. (2010). Vitamin D deficiency in adults: When to test and how to treat. BMJ, 340, c1352.
• Khalsa, P. S., et al. (2007). Manual therapy in patients with osteoporosis: Safety considerations. Journal of Manipulative and Physiological Therapeutics, 30(1), 2–9.
• Marcocci, C., Bollerslev, J., D’Amour, P., & Khan, A. A. (2014). Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3607–3618.
• Marx, S. J. (2018). Familial hypocalciuric hypercalcemia: Clinical and molecular characteristics. Journal of Endocrinological Investigation, 41(11), 1321–1332.
• Peacock, M. (2011). Primary hyperparathyroidism and the role of cinacalcet. Endocrine Practice, 17(Supplement 1), 57–63.
• Robling, A. G., et al. (2006). Mechanical signals and bone. Nature Reviews Molecular Cell Biology, 7(5), 392–402.
• Silverberg, S. J. (2018). Primary hyperparathyroidism. New England Journal of Medicine, 379(12), 1179–1180.
• Spiegel, K., et al. (1999). Impact of sleep on endocrine regulation. The Lancet, 354(9188), 1435–1439.
• Starker, L. F., et al. (2011). The utility of 4D-CT in localization for primary hyperparathyroidism. Annals of Surgical Oncology, 18(7), 1947–1953.
• Stewart, A. F. (2005). Hypercalcemia associated with cancer. New England Journal of Medicine, 352(4), 373–379.
• Udelsman, R., Åkerström, G., Biagini, C., Duh, Q. Y., Miccoli, P., & Rudofsky, G. (2014). The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3595–3606.

SEO Tags: hyperparathyroidism, primary hyperparathyroidism, parathyroid hormone, PTH, hypercalcemia, calcium, ionized calcium, vitamin D, cholecalciferol, ergocalciferol, calcitriol, nephrolithiasis, osteoporosis, parathyroidectomy, sestamibi, 4D-CT, cinacalcet, bisphosphonates, denosumab, functional medicine, chiropractic care, integrative medicine, internal medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, El Paso TX, osteitis fibrosa cystica, multiple endocrine neoplasia, MEN syndrome, familial hypocalciuric hypercalcemia, FHH, DEXA scan, quality of life, observation vs surgery, rehabilitation